Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part I

Voprosy Pitaniia

Volumn 84, Issue 4, 2015, Pages 18-24

  Chernyak, O O ^a   Sentsova, T B ^a   Vorozhko, I V ^a   Tutelyan, V A ^a   Gapparova, K M ^a   Isakov, V A ^a  

^a FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

Author keywords

Gene; Metabolism; Nonalcoholic fatty liver disease; Obesity; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYTOKINE; FABP1 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LIPID;

ADOLESCENT; ADULT; AGED; COMPLICATION; ECHOGRAPHY; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROTEOMICS;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEINS E; BIOMARKERS; CELL ADHESION MOLECULES; CYTOKINES; FATTY ACID-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; LIPIDS; MALE; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROTEOMICS;

EID: 84960993742     PISSN: 00428833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aslafyeva N. G., Gamova I. V., Udovichenko E. N. et al. Obesity and asthma. Lech Vrach. 2014; Vol. 5:100-6. (in Russian)
2. Bogdanov A. R., Derbeneva S. A., Pogozheva A. V. et al. Evaluating the effectiveness of diet therapy in patients with varying degrees of obesity. Vopr Pitan [Problems of Nutrition]. 2014. Vol. 83(6):32-40. (in Russian)
3. Butrova S. A., Dzgoeva F. H. Modern therapy of obesity. Rus Med J. 2005; Vol. 13(2):96-9. (in Russian)
4. Vovk E. I. Treatment of nonalcoholic fatty liver disease in the practice of the therapist: what? where? when? Rus Med J. 2011; Vol. 17:1038-46. (in Russian)
5. Dedov I.I., Melnichenko G. A. Obesity: etiology, pathogenesis, clinical aspects. Manual for Physicians. Moscow: Medical News Agency, 2004:456 p. (in Russian)
6. Dmitriev A. N., Perminov L. R. Diagnostic criteria of the presimptomatic (premorbid) stage of metabolic syndrome. Obes and Metab. 2014; N 4:24-8. (in Russian)
7. Zinoviev E. N., Mehtiev S. N., Sokolov S. V. Endothelial dysfunction as a factor in the progression of non-alcoholic steatohepatitis. Therapeutic approaches. Gastroenterology. 2011; Vol. 1:3-9. (in Russian)
8. Ivashkin V. T., Shulpekova J. O. NASH. Rus Med J Diseases of the Digestive System. 2000; Vol. 2:41-5. (in Russian)
9. Pogozheva A. V., Baturin A. K., Tutelyan V. A. et al. The study of polymorphism rs9939609 FTO gene in patients with overweight and obesity. Vopr Pitan [Problems of Nutrition]. 2011; N 3:13-7. (in Russian)
10. Sorokina E. Y., Sointseva T. N., Radzhabkadiev R. M. et al. Identification of genetic polymorphisms associated with overweight in athletes of winter sports. Vopr Pitan [Problems of Nutrition]. 2013; N 6:58-61. (in Russian)
11. Shulpekova J. O. Pathogenetic significance of lipids in nonalcoholic fatty liver disease. Rossiyskiyzhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2012; Vol. 22(1):45-56. (in Russian)
12. Bellentani S., Scaglioni R, Marino M. et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis Sci. 2010; Vol. 28:155-61.
13. Choromanska B., Mysliwiec P., Dadan J. et al. The clinical significance of fatty acid binding proteins. Postepy Hig Med Dosw. 2011; Vol. 65:759-63.
14. Conlon A., Beasley J. M., Aebersold K. et al. Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). Nutrients. 2013; Vol. 5(10):4093-114.
15. Farrell G. C., van Rooyen D., Gan L. et al. Nash is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. Gut Liver J. 2012; N 6:149-71.
16. Gaggini M., Morelli M., Buzzigoli E. et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; Vol. 5:1544-60.
17. Johnson A. M., Olefsky J. M. The origins and drivers of insulin resistance. Cell. 2013; Vol. 152:673-84.
18. Lopez M. F., Krastins B., Ning M. The role of apolipoprotein E in neurodegeneration and cardiovascular disease. Expert Rev Proteomics. 2014; Vol. 11(3):371-81.
19. Morariu A. M., Loef B. G., Aarts L. P. et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest. 2005; Vol. 128:2677-87.
20. Ozenirler S., Degertekin C. K., Erkan G. et al. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013; Vol. 60(125):1095-100.
21. Pelsers M. M. Fatty acid-binding proteins as plasma markers of tissue injury. Scand J Clin Lab Invest Suppl. 2008; Vol. 241:73-7.
22. Pelsers M. M., Morovat A., Alexander G. J. et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002; Vol. 48:2055-7.
23. Smith B. W., Adams L. A. Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment. Nat Rev Endocrinol. 2011; Vol. 7:456-65.
24. Withrow D., Alter D. A. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011; Vol. 12:131-4.